{"entity":{"id":"nct06775483","kind":"trial","name":"Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical Study","aka":[],"tldr":"A phase 2 trial of JSKN016 and docetaxel in lung cancer, run by Jiangsu Alphamab Biopharmaceuticals Co., Ltd, not yet recruiting.","summary":"Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical Study is a phase 2, randomised interventional study registered as NCT06775483 by Jiangsu Alphamab Biopharmaceuticals Co., Ltd, with a registry enrolment figure of 220 participants, started 2025-01-17 and due to reach its primary completion in 2027-06-30. Interventions recorded: JSKN016; Docetaxel. Conditions listed: Advanced Non-small Cell Lung Cancer. Primary outcome: ORR assessed by the investigator per RECIST v1.1; Safety reflected by AE. Lung eligibility wording from the registry: \"Histologically or cytologically confirmed locally advanced or metastatic non-small cell lung cancer (NSCLC) that is not suitable for radical surgery and/or radical radiotherapy, and meets one of the following conditions: EGFR sensitive mutations, and failed treatment with EGFR-TKI; Driver gene negat\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT06775483","url":"https://clinicaltrials.gov/study/NCT06775483"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["jskn016","docetaxel"],"companies":["alphamab"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06775483","phase":"2","setting":"Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical Study","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","enrolled":220,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06775483/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"},{"id":"jskn016","kind":"drug","name":"JSKN016","route":"/drugs/jskn016/"}],"company":[{"id":"alphamab","kind":"company","name":"Alphamab Oncology","route":"/companies/alphamab/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}